Skip to Content
Merck
All Photos(1)

Key Documents

390585

Sigma-Aldrich

Suberohydroxamic acid

95%

Synonym(s):

N,N′-Dihydroxyoctanediamide, SBHA, Suberoyl bis-hydroxamic acid

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
[-(CH2)3CONHOH]2
CAS Number:
Molecular Weight:
204.22
MDL number:
UNSPSC Code:
12352100
PubChem Substance ID:
NACRES:
NA.22

Quality Level

Assay

95%

mp

153-155 °C (lit.)

functional group

amine

SMILES string

ONC(=O)CCCCCCC(=O)NO

InChI

1S/C8H16N2O4/c11-7(9-13)5-3-1-2-4-6-8(12)10-14/h13-14H,1-6H2,(H,9,11)(H,10,12)

InChI key

IDQPVOFTURLJPT-UHFFFAOYSA-N

Biochem/physiol Actions

Suberoyl bis-hydroxamic acid (SBHA) is a Histone deacetylase (HDAC) inhibitor. SBHA inhibits the activity of HDAC1 and HDAC3 with IC50 values of 250 and 300 nM, respectively. SBHA inhibits proliferation, and induces apoptosis in several cancer cell lines. SBHA has been shown to activate Notch signaling in medullary thyroid carcinoma (MTC) cells.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Li Ning et al.
The oncologist, 13(2), 98-104 (2008-02-29)
Medullary thyroid carcinoma (MTC) is a neuroendocrine (NE) malignancy that frequently metastasizes and has limited treatments. We recently reported that ectopic expression of Notch-1 in human MTC cells suppresses growth. The objective of this study was to evaluate the ability
Jiansen Li et al.
Oncology reports, 37(1), 458-464 (2016-12-23)
Anaplastic thyroid cancer (ATC), usually derived from well-differentiated thyroid cancers is one of the most lethal human endocrine malignancies. In the present study, we report that in human ATC tumor tissue samples exist undetectable Notch1 and the active Notch1 intracellular
Mohamed Rahmani et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(18), 4849-4860 (2014-07-30)
The aim of this study is to explore the efficacy and define mechanisms of action of coadministration of the PI3K/mTOR inhibitor BEZ235 and pan-HDAC inhibitor panobinostat in diffuse large B-cell lymphoma (DLBCL) cells. Various DLBCL cells were exposed to panobinostat
Denisa Hrckova Drozdkova et al.
Anticancer research, 40(9), 4979-4987 (2020-09-04)
Multiple myeloma is a highly heterogeneous disease of clonal plasma cells. Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their precise mechanisms of actions are not well understood. Cell-cycle regulation and pro-apoptotic effects of two histone deacetylase inhibitors, suberohydroxamic
Shuang Chen et al.
Blood, 124(17), 2687-2697 (2014-09-12)
Bim contributes to resistance to various standard and novel agents. Here we demonstrate that Bim plays a functional role in bortezomib resistance in multiple myeloma (MM) cells and that targeting Bim by combining histone deacetylase inhibitors (HDACIs) with BH3 mimetics

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service